Dual antithrombotic therapy using dabigatran significantly reduces risk of bleeding compared to triple therapy using warfarin.
The risk of intraocular bleeding was reduced by one-fifth when using newer anticoagulants versus warfarin in a new study.
Rivaroxaban (Xarelto, Janssen/ Bayer) has been found to significantly reduce the risk of strokes and heart attacks in patients with artery disease.
Education about anticoagulants helped boost adherence rates and led to a small decrease in stroke risk.
The high risk of bleeding in patients taking the anticoagulant dabigatran (Pradaxa) has been a major problem that the manufacturer and health experts have been trying to find solutions for over the last four years. Sixteen percent of patients experienced a bleed in one year, including 3.3% who had bleeds that required emergency medical treatment, according to one clinical trial.
Warfarin use may be safe following a heart attack in patients with both atrial fibrillation and chronic kidney disease, according to a Swedish study of more than 24,000 patients.
The Office of Disease Prevention and Health Promotion under the Department of Health and Human Services (HHS) is calling for public review and comments on its draft plan to reduce adverse drug events that are preventable. The deadline is Friday, Oct. 4 to email feedback to [email protected].